헬리코박터 파일로리 감염의 진단과 치료

키워드

참고문헌 (56)

1. 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
2. Gisbert JP, "Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori in-fection: a systematic review and meta-analysis", Am J Gastroenterol, 101, pp.1921~1930 (2006)
3. Kim JM, "Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients", Int J Antimicrob Agents, 28, pp.6~13 (2006)
4. Kim JM, "Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients", J Antimicrob Chemother, 56, pp.965~967 (2005)
5. Gramley WA, "Detection of Helicobacter pylori DNA in fecal samples from infected individuals", J Clin Microbiol, 37, pp.2236~2240 (1999)
6. Song Q, "Helicobacter pylori in dental plaque: a comparison of different PCR primer sets", Dig Dis Sci, 44, pp.479~484 (1999)
7. Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea", Antimicrob Agents Chemother, 48, pp.4843~4847 (2004)
8. Choi KD, "Analysis of the 3' variable region of the cagA gene of Helicobacter pylori isolated in Koreans", Dig Dis Sci, 52, pp.960~966 (2007)
9. 김나영, "헬리코박터 파일로리 감염의 진단 및 치료 가이드라인", 대한소화기학회지, 54(5), pp.269~278 (2009), 대한소화기학회
10. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
11. 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
12. De Francesco V, "Worldwide H. pylori antibiotic resistance: a systematic review", J Gastrointestin Liver Dis, 19, pp.409~414 (2010)
13. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
14. Malfertheiner P, "Management of Helicobacter pylori infection--the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
15. Fock KM, "Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection", J Gastroenterol Hepatol, 24, pp.1587~1600 (2009)
16. 이주엽, "헬리코박터 제균 치료의 미래", 대한소화기학회지, 63(3), pp.158~170 (2014), 대한소화기학회
17. 김승영, "국내 Helicobacter pylori 의 제균 치료", 대한소화기학회지, 58(2), pp.67~73 (2011), 대한소화기학회
18. Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
19. 윤재훈, "Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication", Gut and Liver, 6(4), pp.434~439 (2012), 거트앤리버 발행위원회
20. Gené E, "Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis", Aliment Pharmacol Ther, 17, pp.1137~1143 (2003)
21. Luther J, "Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability", Am J Gastroenterol, 105, pp.65~73 (2010)
22. Venerito M, "Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection", Digestion, 88, pp.33~45 (2013)
23. Jafri NS, "Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment", Ann Intern Med, 148, pp.923~931 (2008)
24. Gatta L, "Sequential therapy or triple therapy for Helicobacter pylori infection:systematic review and meta-analysis of randomized controlled trials in adults and children", Am J Gastroenterol, 104, pp.3069~3079 (2009)
25. Tong JL, "Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis", J Clin Pharm Ther, 34, pp.41~53 (2009)
26. Yoon H, "Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?", J Gastroenterol Hepatol, 28, pp.1801~1809 (2013)
27. 김준성, "Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis", Gut and Liver, 7(5), pp.546~551 (2013), 거트앤리버 발행위원회
28. Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
29. Gisbert JP, "Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori", Aliment Pharmacol Ther, 34, pp.604~617 (2011)
30. Essa AS, "Meta-analysis:four-drug, three-antibiotic, non-bismuth-containing “conco-mitant therapy” versus triple therapy for Helicobacter pylori eradication", Helicobacter, 14, pp.109~118 (2009)
31. Gisbert JP, "Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori", Clin Exp Gastroenterol, 5, pp.23~34 (2012)
32. Kim SY, "Comparative study of Helicobacter pylori eradication rates with 5-day quadruple “concomitant” therapy and 7-day standard triple therapy", J Clin Gastroenterol, 47, pp.21~24 (2013)
33. Lim JH, "Clinical outcomes of twoweek sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study", Helicobacter, 18, pp.180~186 (2013)
34. Wu DC, "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection", Clin Gastroenterol Hepatol, 8, pp.36~41.e1 (2010)
35. Huang YK, "Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication", J Dig Dis, 13, pp.232~238 (2012)
36. McNicholl AG, "Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice", Gut, 63, pp.244~249 (2014)
37. Hsu PI, "Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7days", Helicobacter, 16, pp.139~145 (2011)
38. Molina-Infante J, "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance", Gastroenterology, 145, pp.121~128.e1 (2013)
39. Oh DH, "Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy", J Gastroenterol Hepatol, 29, pp.1171~1176 (2014)
40. De Francesco V, "Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study", J Med Microbiol, 63(Pt 5), pp.748~752 (2014)
41. Saad RJ, "Levofloxacinbased triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a metaanalysis", Am J Gastroenterol, 101, pp.488~496 (2006)
42. Gisbert JP, "Systematic review and meta-analysis:levofloxacin-based rescue regimens after Helicobacter pylori treatment failure", Aliment Pharmacol Ther, 23, pp.35~44 (2006)
43. 이지현, "Helicobacter pylori 제균치료에서 Levofloxacin 병합요법의 효과", 대한소화기학회지, 48(1), pp.19~24 (2006), 대한소화기학회
44. 강문수, "Levofloxacin-Azithromycin 병합 삼제요법을 이용한 Helicobacter pylori 제균", 대한소화기학회지, 47(1), pp.30~36 (2006), 대한소화기학회
45. Yoon H, "Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate", Helicobacter, 14, pp.77~85 (2009)
46. Kang KK, "Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea", World J Gastroenterol, 20, pp.6932~6938 (2014)
47. Gisbert JP, "Review article: rifabutin in the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 35, pp.209~221 (2012)
48. 정명호, "헬리코박터 파일로리의 3차 구제요법에서 리파부틴과 레보플록사신의 비교", 대한소화기학회지, 59(6), pp.401~406 (2012), 대한소화기학회[DOI]
49. Suzuki S, "Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori", Digestion, 79, pp.1~4 (2009)
50. O'Connor A, "Treatment of Helicobacter pylori infection 2011", Helicobacter, 16(Suppl 1), pp.53~58 (2011)
51. Szajewska H, "Meta-analysis:the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment", Aliment Pharmacol Ther, 32, pp.1069~1079 (2010)
52. Zou J, "Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication", Helicobacter, 14, pp.97~107 (2009)
53. Woo HY, "Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens", Helicobacter, 14, pp.22~28 (2009)
54. Toracchio S, "Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication", Aliment Pharmacol Ther, 14, pp.1639~1643 (2000)
55. Molina-Infante J, "Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains", Helicobacter, 17, pp.269~276 (2012)
56. Dickson EJ, "Genetics of response to proton pump inhibitor therapy: clinical implications", Am J Pharmacogenomics, 3, pp.303~315 (2003)

관련 논문AI추천